{"id":"NCT01654250","sponsor":"Pfizer","briefTitle":"NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2012-07-31","resultsPosted":"2016-02-03","lastUpdate":"2016-02-03"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":null,"masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"NWP09","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD","primaryOutcome":{"measure":"Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores-Average of All Post-Dose Time-Points","timeFrame":"0.75 up to 13 hours post-dose","effectByArm":[{"arm":"Placebo (OL Phase; DB Phase)","deltaMin":19.1,"sd":1.39},{"arm":"NWP09 (OL Phase; DB Phase)","deltaMin":12.1,"sd":1.41}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":["28557548"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=NWP09-ADHD-300&StudyName=NWP09%20in%20Children%20with%20Attention%20Deficit%20Hyperactivity%20Disorder%20%28ADHD%29"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":44},"commonTop":["Decreased appetite","Upper respiratory tract infection","Mood swings","Abdominal pain upper","Irritability"]}}